Patents Assigned to Schering Corporations
  • P1-NONEPIMERIZABLE KETOAMIDE INHIBITORS OF HCV NS3 PROTEASE
    Publication number: 20100074867
    Abstract: The present invention discloses novel compounds, which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Application
    Filed: March 20, 2008
    Publication date: March 25, 2010
    Applicant: Schering Corporation Patent Department, K-6-1; 1990
    Inventors: Srikanth Venkatraman, F. George Njoroge, Francisco Velazquez, Wanli Wu, Vincent S. Madison, Neng-Yang Shih
  • METHOD FOR REDUCING PROTEASE ACTIVITY IN PLANT HYDROLYSATE
    Publication number: 20100075415
    Abstract: The present invention provides methods for reducing protease activity in plant hydrolysates that are utilized in cell culture media. The method involves a combination of heating and ultrafiltration to remove proteases present in the hydrolysate prior to the addition of the hydrolysate to the cell culture medium.
    Type: Application
    Filed: November 13, 2007
    Publication date: March 25, 2010
    Applicant: SCHERING CORPORATION
    Inventor: Kimberly M. May
  • Compounds for the treatment of inflammatory disorders
    Patent number: 7683088
    Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-? or combinations thereof.
    Type: Grant
    Filed: January 16, 2007
    Date of Patent: March 23, 2010
    Assignee: Schering Corporation
    Inventors: Brian J. Lavey, Joseph A. Kozlowski, Guowei Zhou, Ling Tong, Wensheng Yu, Michael K. C. Wong, Bandarpalle B. Shankar, Neng-Yang Shih, M. Arshad Siddiqui, Kristin E. Rosner, Chaoyang Dai, Janeta Popovici-Muller, Vinay M. Girijavallabhan, Dansu Li, Aneta M. Micula, Seong-Heon Kim, De-Yi Yang, Razia Rizvi
  • Compounds for the treatment of inflammatory disorders
    Patent number: 7683085
    Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF- or combinations thereof.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: March 23, 2010
    Assignee: Schering Corporation
    Inventors: Wensheng Yu, Ling Tong, Lei Chen, Joseph A. Kozlowski, Brian J. Lavey, Neng-Yang Shih, Vincent S. Madison, Guowei Zhou, Peter Orth, Zhuyan Guo, Michael K. C. Wong, De-Yi Yang, Seong Heon Kim, Bandarpalle B. Shankar
  • ASPARTYL PROTEASE INHIBITORS
    Publication number: 20100069406
    Abstract: Disclosed are compounds of formula I (Chemical formula should be inserted here as it appears on abstract in paper form) Formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R4, R14, V, W, X, Y, Z, p, and ring A are as described in the specification. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.
    Type: Application
    Filed: December 10, 2007
    Publication date: March 18, 2010
    Applicant: Schering Corporation
    Inventors: Zhaoning Zhu, Andrew Stamford, Mihirbaran Mandal, Xiaoxiang Liu
  • Synthesis of 3-(5-nitrocyclohex-1-enyl) acrylic acid and esters thereof
    Patent number: 7678948
    Abstract: This application discloses provides a process for the introduction of nitro-group functionality into a compound which contains also a site of unsaturation and/or oxygen functionality by direct (one step) oxidation of an oxime functional group mediated by a molybdenum VI/VII peroxo complex, the process comprising: (a) providing a substrate of Formula I containing an oxime functional group; wherein R1 and R2 are selected independently from linear, branched or cyclic alkyl and linear, branched or cyclic alkenyl groups, optionally substituted, with the proviso that at least one of R1 or R2 contains a carbon/carbon double bond; and (b) contacting said substrate of Formula I with a molybdenum oxidation complex, thereby oxidizing said oxime functional group to a nitro functional group to yield the structure of Formula III. Where R1 and R2 are as defined above.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: March 16, 2010
    Assignee: Schering Corporation
    Inventors: Tiruvettipuram K. Thiruvengadam, Tao Wang, John S. Chiu, Jing Liao
  • Processes of making and using pharmaceutical formulations of antineoplastic agents
    Patent number: 7674790
    Abstract: In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.
    Type: Grant
    Filed: January 13, 2006
    Date of Patent: March 9, 2010
    Assignee: Schering Corporation
    Inventors: Sydney Ugwu, Vinay Radhakrishnan, Peter M. Ihnat, Leonore C. Witchey-Lakshmanan
  • Isothiazole dioxides as CXC- and CC-chemokine receptor ligands
    Patent number: 7671212
    Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.
    Type: Grant
    Filed: December 20, 2004
    Date of Patent: March 2, 2010
    Assignee: Schering Corporation
    Inventors: Arthur G. Taveras, J. Robert Merritt, John J. Baldwin, Junying Zheng, Purakkattle J. Biju, Younong Yu, Jianhua Chao, Gaifa Lai, Minglang Wu
  • Human DNAX toll-like receptor 4 proteins, related reagents and methods
    Patent number: 7670603
    Abstract: Nucleic acids encoding mammalian Toll-like receptors (TLRs) have been identified in human cells. Recombinantly produced TLRs are used in the preparation of antibodies that are capable of binding to the TLRs. The antibodies are advantageously used in the prevention and treatment of septic shock, inflammatory conditions, and viral infections.
    Type: Grant
    Filed: April 9, 2008
    Date of Patent: March 2, 2010
    Assignee: Schering Corporation
    Inventors: Gerard T. Hardiman, Fernando L. Rock, J. Fernando Bazan, Robert A. Kastelein, Stephen W. K. Ho, Yong-Jun Liu
  • Neutralizing human anti-IGFR antibody
    Patent number: 7667021
    Abstract: The present invention includes isolated nucleic acids encoding fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). Also included are methods of using and producing the antibodies of the invention.
    Type: Grant
    Filed: November 13, 2006
    Date of Patent: February 23, 2010
    Assignee: Schering Corporation
    Inventors: Yan Wang, Robert Greenberg, Leonard Presta, Jonathan A. Pachter, Judith Hailey, Peter Brams, Denise Williams, Mohan Srinivasan, Diane Feingersh
  • Mammalian Cytokine; Related Reagents
    Publication number: 20100041144
    Abstract: Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Application
    Filed: October 20, 2009
    Publication date: February 18, 2010
    Applicant: SCHERING CORPORATION
    Inventor: J. Fernando Bazan
  • Interleukin-10 antibodies
    Patent number: 7662379
    Abstract: The methods and compositions provided herein relate generally to IL-10 specific antibodies and uses thereof. More specifically, the methods and compositions provided herein relate to humanized IL-10 specific antibodies and methods to use such antibodies in modulating the biological activity of IL-10, particularly in autoimmune disorders and pathogen-mediated immunopathology.
    Type: Grant
    Filed: January 12, 2007
    Date of Patent: February 16, 2010
    Assignee: Schering Corporation
    Inventor: Leonard G. Presta
  • Cyclic amine BACE-1 inhibitors having a benzamide substituent
    Patent number: 7662816
    Abstract: Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is R is —C(O)—N(R27)(R28) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a ?-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.
    Type: Grant
    Filed: August 4, 2004
    Date of Patent: February 16, 2010
    Assignee: Schering Corporation
    Inventors: Jared N. Cumming, Ulrich Iserloh, Andrew Stamford, Corey Strickland, Johannes H. Voigt, Yusheng Wu, Ying Huang, Yan Xia, Samuel Chackalamannil, Tao Guo, Douglas W. Hobbs, Thuy X. H. Le, Jeffrey F. Lowrie, Kurt W. Saionz, Suresh D. Babu
  • Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors
    Patent number: 7659275
    Abstract: In its many embodiments, the present invention provides a novel class of compounds of structural formula IA or IB where R1-R8 are as disclosed herein as inhibitors of the CCR5 receptors, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with CCR5 using such compounds or pharmaceutical compositions. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v.
    Type: Grant
    Filed: February 21, 2006
    Date of Patent: February 9, 2010
    Assignee: Schering Corporation
    Inventors: Tze-Ming Chan, Kathleen Kox, Wenqing Feng, Michael W. Miller, Daniel Weston, Stuart W. McCombie
  • DAP12 nucleic acids
    Patent number: 7659093
    Abstract: The purification and isolation of various genes which encode mammalian cell surface polypeptides. Nucleic acids, proteins, antibodies, and other reagents useful in modulating development of cells, e.g., lymphoid and myeloid, are provided, along with methods for their use.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: February 9, 2010
    Assignee: Schering Corporation
    Inventors: Alexander B. H. Bakker, Joseph H. Phillips, Lewis L. Lanier
  • COMPOSITIONS AND METHODS FOR THERAPEUTIC USE
    Publication number: 20100028431
    Abstract: A method and pharmaceutical composition for the enhancement of transfer of a therapeutic agent to a cell wherein the therapeutic agent is formulated in a buffer comprising a compound of Formula I: wherein: n is an integer from 2-8; X1 is a cholic acid group or deoxycholic acid group; and X2 and X3 are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose disaccharide groups; and wherein at least one of X2 and X3 is a saccharide group.
    Type: Application
    Filed: April 13, 2009
    Publication date: February 4, 2010
    Applicants: Canji Inc.,, Schering Corporation,
    Inventors: Heidrun Engler, Tattanahalli L. Nagabhushan, Stephen Kenneth Youngster
  • IL-17-like cytokine binding compounds and antibodies
    Patent number: 7655761
    Abstract: CTLA-8 related antigens from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigens. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: December 7, 2007
    Date of Patent: February 2, 2010
    Assignee: Schering Corporation
    Inventors: Daniel M. Gorman, J. Fernando Bazan, Robert A. Kastelein, Gerard Zurawski
  • Expression of soluble heterologous proteins in bacteria utilizing a thioredoxin/protein expression vector
    Patent number: 7655436
    Abstract: A method for producing a soluble, properly folded, biologically active protein in bacteria in which the heterologous protein is coexpressed with a thioredoxin protein.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: February 2, 2010
    Assignee: Schering Corporation
    Inventors: Paula D. Ravnikar, Robert Greenberg
  • EXTENDED RELEASE ORAL DOSAGE COMPOSITION
    Publication number: 20100021542
    Abstract: A bilayer solid composition comprising (a) an immediate release first layer comprising an anti-allergic effective amount of desloratadine and at least one pharmaceutically acceptable excipient and (b) a sustained release second layer comprising an effective amount of a nasal decongestant, e.g. pseudoephedrine sulfate and a pharmaceutically acceptable sustained release agent wherein the composition contains less than about 2% of desloratadine decomposition products is disclosed. A solid composition comprising an anti-allergic effective amount of desloratadine and at least one, and preferably two pharmaceutically acceptable antioxidants is also disclosed.
    Type: Application
    Filed: October 2, 2009
    Publication date: January 28, 2010
    Applicant: Schering Corporation
    Inventor: Wing-Kee Philip Cho
  • Compounds for the treatment of inflammatory disorders
    Patent number: 7652020
    Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-? or combinations thereof.
    Type: Grant
    Filed: June 1, 2005
    Date of Patent: January 26, 2010
    Assignee: Schering Corporation
    Inventors: Zhuyan Guo, Peter Orth, Zhaoning Zhu, Robert D. Mazzola, Tin-Yau Chan, Henry A. Vaccaro, Brian McKittrick, Joseph A. Kozlowski, Brian J. Lavey, Guowei Zhou, Sunil Paliwal, Shing-Chun Wong, Neng-Yang Shih, Pauline C. Ting, Kristin E. Rosner, Gerald W. Shipps, Jr., M. Arshad Siddiqui, David B. Belanger, Chaoyang Dai, Dansu Li, Vinay M. Girijavallabhan, Janeta Popovici-Muller, Wensheng Yu, Lianyun Zhao